Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?

被引：0
|
作者：
GianMaria Miolo
Ettore Bidoli
Davide Lombardi
Davide Adriano Santeufemia
Giampiero Capobianco
Francesco Dessole
Simona Scalone
Simon Spazzapan
Roberto Sorio
Gianna Tabaro
Andrea Veronesi
机构：
[1] Centro di Riferimento Oncologico,Department of Oncology, Division of Medical Oncology C
[2] National Cancer Institute,Epidemiology and Biostatistics Unit
[3] Centro di Riferimento Oncologico,Department of Oncology, Division of Medical Oncology
[4] National Cancer Institute,undefined
[5] Pordenone Hospital,undefined
[6] Gynecologic and Obstetric Clinic,undefined
[7] University of Sassari,undefined
来源：
Archives of Gynecology and Obstetrics | 2012年 / 285卷
关键词：
Chemotherapy; Dose density; Ovarian carcinoma; Weekly paclitaxel;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：499 / 503
页数：4
相关论文
共 50 条
  • [31] Weekly paclitaxel treatment of patients with progressive platinum resistant epithelial ovarian cancer.
    Le, T
    Baines, KA
    Rambout, L
    Rezaifer, P
    Al Hayki, M
    Hopkins, L
    Fung, MFK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 488S - 488S
  • [32] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer
    Adam, Jean-Philippe
    Boumedien, Feriel
    Letarte, Nathalie
    Provencher, Diane
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 47 - 53
  • [33] Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer
    Ghamande, S
    Lele, S
    Marchetti, D
    Baker, T
    Odunsi, K
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (02) : 142 - 147
  • [34] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Chura, Justin C.
    Van Iseghem, Kelin
    Downs, Levi S., Jr.
    Carson, Linda F.
    Judson, Patricia L.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
  • [35] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, G.
    Kucukzeybek, Y.
    Kemal-Gul, M.
    Karaca, B.
    Cosan-Terek, M.
    Karabulut, B.
    Sanli, U. A.
    Akman, L.
    Ozsaran, A.
    Dikmen, Y.
    Uslu, R.
    JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
  • [36] The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience
    Hu, Ching-Fen
    Ou, Yu-Che
    Fu, Hung-Chun
    Chien, Chan-Chao Chang
    Tsai, Chin-Chou
    Wu, Chen-Hsuan
    Lin, Hao
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2015, 54 (01): : 43 - 47
  • [37] Weekly paclitaxel in pretreated metastatic breast cancer: Retrospective analysis of 52 patients
    Baltali, E
    Altundag, K
    Ozisik, Y
    Guler, N
    Tekuzman, G
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 203 (03): : 205 - 210
  • [38] Topotecan as single agent or in combination with carboplatin in pretreated and heavily pretreated patients with advanced ovarian cancer
    Martoni, A
    Pelusi, G
    De Jaco, P
    Taroni, B
    Cacciari, N
    Angelelli, B
    Marino, A
    Zamagni, C
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 253 - 256
  • [39] High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients
    Vici, P
    Capomolla, E
    Foggi, P
    Carpano, S
    Conti, F
    Paoletti, G
    Cauchi, C
    Giacinti, L
    Leonetti, C
    Giannarelli, D
    Lopez, M
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2006, 25 (01): : 39 - 44
  • [40] Retrospective analysis of topotecan administered weekly in heavily pretreated recurrent epithelial ovarian carcinoma patients.
    O'Malley, D
    Makkenchery, A
    Tangir, J
    Kelly, M
    Azodi, M
    Chambers, S
    Schwartz, P
    Rutherford, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 468S - 468S
12345